Irinotecano Farmoz

Irinotecan, the active ingredient in Irinotecano Farmoz, is a topoisomerase I inhibitor presented as a sterile lyophilized powder for intravenous use. It is employed in oncology protocols to treat colorectal cancer and other solid tumours in adult patients. The drug is indicated for use in combination chemotherapy regimens and is manufactured according to European Union quality standards.

GNH USA supplies Irinotecano Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance.

Irinotecan is used in chemotherapy regimens targeting colorectal cancer and other solid tumours.

- Colorectal cancer: improves response rates and overall survival when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used in combination protocols to enhance tumour control. - Pancreatic cancer: incorporated into multi‑agent regimens for disease management. - Non‑small cell lung cancer: added to standard chemotherapy to increase efficacy.

Irinotecan may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count leading to infection risk. - Diarrhea: frequent loose stools that may require supportive care. - Nausea and vomiting: gastrointestinal upset commonly observed during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis (ileocolitis): intense abdominal pain and bloody diarrhea. - Allergic reactions: rash, bronchospasm or anaphylaxis in susceptible patients.

Before initiating Irinotecano Farmoz, clinicians should observe several precautionary measures to minimise toxicity.

- Monitor blood counts: perform regular complete blood count assessments to detect neutropenia early. - Assess liver function: evaluate hepatic enzymes because impaired metabolism increases SN‑38 exposure. - Evaluate bowel health: screen for pre‑existing diarrhoea or intestinal obstruction before treatment. - Adjust dose in hepatic or renal impairment: consider reduced dosing in patients with significant organ dysfunction. - Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce SN‑38 levels and therapeutic effect. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): increase SN‑38 exposure and risk of severe neutropenia or diarrhea. - Concurrent myelosuppressive agents (e.g., high‑dose cyclophosphamide): can exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced bleeding risk due to potential liver enzyme interactions. - Antidiarrheal agents (e.g., loperamide): may mask early signs of irinotecan‑induced diarrhea. - Other topoisomerase inhibitors: additive toxicity may require dose adjustments.